The National Institute on Aging, in Bethesda, Md, is joining other federal
agencies and some pharmaceutical companies to conduct a $60 million effort
to study Alzheimer disease. The Alzheimer’s Disease Neuroimaging Initiative
will track changes in the brains of 800 participants aged 55 to 90 years.
The study will include 200 individuals with normal cognition, 400 with mild
cognitive impairment, and 200 with early-stage Alzheimer disease.
The goal is to test whether serial magnetic resonance imaging, positron
emission tomography, and clinical and neuropsychological assessment can be
combined to measure the progression of mild cognitive impairment and early
Alzheimer disease. The study could help researchers develop new treatments
and monitor the effectiveness of therapies during clinical trials.
Hampton T. Alzheimer Study to Recruit Patients. JAMA. 2004;292(24):2963. doi:10.1001/jama.292.24.2963-a